nRichDX to present its latest research and advanced liquid biopsy solutions at AMP 2024

nRichDX^®, best known for its Revolution Sample Prep System™ for liquid biopsy, will display its latest products, present new data, and exhibit at the Association for Molecular Pathology (AMP) Annual Meeting 2024, from November 19–23 at the Vancouver Convention Centre, in Vancouver, Canada.

The meeting is devoted to exploring and recognizing the latest discoveries in molecular pathology and precision medicine. At nRichDX's booth, meeting attendees can see the latest liquid biopsy sample prep solutions and learn more about how extracting higher yields of these analytes can increase assay performance through better sensitivity and earlier detection of targeted oncology markers.

The booth will feature the Revolution Plus™ instrument and a preview of the Revolution Pro™ instrument being introduced in 2025. Both automated sample prep solutions exclusively process nRichDX's unique nRicher™ cartridges.

The new nRicher Cartridges have the broadest input sample volume range – from as little as 1 mL up to 100 mL in a single extraction – eliminating the tedious and yield-lowering sample transfer, pooling, preconcentration, and re-elution steps often required by other sample prep methods.

"Sample prep yield has been called the critical bottleneck in liquid biopsy – with poor yields primarily responsible for assay failures due to poor sensitivity, false negatives, and QNS errors. Existing sample prep methods are a big part of liquid biopsy's sensitivity problem," said William Curtis, CEO of nRichDX. "Revolution Sample Prep is engineered to solve liquid biopsy's sensitivity problem by delivering higher yields of rare analytes with a simpler, scalable workflow. I particularly look forward to meeting AMP 2024 attendees looking for liquid biopsy solutions beyond the status quo."

At least three posters planned for the meeting will include nRichDX solutions:

• Enhanced Extraction and Preservation of Circulating Cell-Free RNA from 50 mL Cell-Free Urine, presented in collaboration with Agilent Technologies
• The Mutational Landscape of Circulating Tumor Cells in Pancreatic Cancer, presented in collaboration with Dartmouth Hitchcock Medical Center
• Clinical Validation of Cell-free DNA (cfDNA) Extraction from Whole Blood Plasma using the nRichDX^® Revolution Max 20 Kit and Sample Prep System, presented in collaboration with Dartmouth Hitchcock Medical Center

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>